Welcome to our dedicated page for Regulus Therapeutics SEC filings (Ticker: RGLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Regulus Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Regulus Therapeutics's regulatory disclosures and financial reporting.
Regulus Therapeutics Inc. (RGLS): Schedule 13G/A disclosure summarizing Point72 filings. Point72 Asset Management, Point72 Capital Advisors Inc. and Steven A. Cohen report beneficial ownership of 241,157 shares, representing 0.3% of the outstanding common stock on a diluted basis. The filing states these shares include shares issuable upon exercise of warrants and that Point72 entities hold shared voting and dispositive power over 241,157 shares with no sole voting or dispositive power. The ownership percentage is calculated using a total of 69,475,246 shares outstanding, which includes the 241,157 warrant shares.
Regulus Therapeutics Inc. is the subject of a Schedule 13G/A filed by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin reporting that none of the reporting persons beneficially own any shares of Regulus common stock. The filing lists 0 shares and 0.00% ownership, with beneficial ownership calculated using an issuer share count of 69,234,089 common shares outstanding.
The reporting persons state the securities were not acquired to influence control of the issuer and that the filing is made on behalf of each undersigned. This disclosure indicates the filers currently hold no economic or voting interest in Regulus and do not represent a change in ownership or control.